Anti-Hypertensive Drugs Have Different Effects on Ventricular Hypertrophy Regression by Filho, Celso Ferreira et al.
CLINICS 2010;65(7):723-8
Copyright © 2010 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REVIEW
I Departamento de Clínica Médica, Disciplina de Cardiologia, Faculdade de 
Medicina do ABC - Santo André/SP, Brasil. 
II Departamento de Morfologia e Fisiologia, Faculdade de Medicina do ABC 
- Santo André/SP, Brasil.
  III Departamento de Medicina, Disciplina de Cardiologia, Universidade 
Federal de São Paulo (UNIFESP) - São Paulo/SP, Brasil. 
IVDepartamento de Fisioterapia da Faculdade de Ciências e Tecnologia, 
Universidade Estadual Paulista ( FCT – UNESP) - Presidente Prudente/ 
SP, Brasil.
Email: celsoferreira.dmed@epm.br / ferreira-celso@uol.com.br
Tel.: 55 11 4993-5403
Received for publication on April 01, 2010
First review completed on April 06, 2010
Accepted for publication on April 06, 2010
ANTI-HYPERTENSIVE DRUGS HAVE DIFFERENT EFFECTS ON VENTRICULAR 
HYPERTROPHY REGRESSION
Celso Ferreira Filho,I Luiz Carlos de Abreu,II Vitor E. Valenti,II, III Marcelo Ferreira,I Adriano Meneghini,I José Alexandre 
Silveira,I Andrés R. Pérez Riera,I Eduardo Colombari,II Neif Murad,I Paulo Roberto Santos-Silva,I Lovian José Henrique 
Pereira da Silva,I Luiz Carlos Marques Vanderlei,IV Tatiana D. Carvalho,III Celso FerreiraI,III 
 
doi: 10.1590/S1807-59322010000700012
Ferreira Filho C, Abreu LC, Valenti VE, Ferreira M, Meneghini A, Silveira JA et al. Anti-hypertensive drugs have different 
effects on ventricular hypertrophy regression. Clinics. 2010;65(7):723-8.
OBJECTIVES: There is a direct relationship between the regression of left ventricular hypertrophy (LVH) and a decreased risk 
of mortality. This investigation aimed to describe the effects of anti-hypertensive drugs on cardiac hypertrophy through a meta-
analysis of the literature.
METHODS: The Medline (via PubMed), Lilacs and Scielo databases were searched using the subject keywords cardiac hypertrophy, 
antihypertensive and mortality. We aimed to analyze the effect of anti-hypertensive drugs on ventricle hypertrophy. RESULTS: The 
main drugs we described were enalapril, verapamil, nifedipine, indapamina, losartan, angiotensin-converting enzyme inhibitors 
and atenolol. These drugs are usually used in follow up programs, however, the studies we investigated used different protocols. 
Enalapril (angiotensin-converting enzyme inhibitor) and verapamil (Ca++ channel blocker) caused hypertrophy to regress in LVH 
rats. The effects of enalapril and nifedipine (Ca++ channel blocker) were similar. Indapamina (diuretic) had a stronger effect than 
enalapril, and losartan (angiotensin II receptor type 1 (AT1) receptor antagonist) produced better results than atenolol (selective β1 
receptor antagonist) with respect to LVH regression. 
CONCLUSION: The anti-hypertensive drugs induced various degrees of hypertrophic regression.
KEYWORDS: Hypertrophy; Cardiomyopathy; Hypertrophic; Left ventricle hypertension; Cardiology.
INTRODUCTION
Cardiac  hypertrophy  consists  of  an  increase  in 
myocardial mass that results in persistent pressure and/
or volume overload.1 In myocytes, hyperplasia is limited 
because of the cells’ differentiated profile, that most closely 
resembles a short period of time that ends immediately after 
birth.1 The high prevalence of ventricular dysfunction is 
used to support the view that the ability to regenerate after 
injury is not significant. However, research has shown that 
myocyte regeneration is fundamental to heart homeostasis.2 
For instance, during aortic stenosis, the combination of 
hypertrophy and hyperplasia increases cardiac mass3 at 
specific locations, such as the site of a therapeutic stem cell 
implant.2
Remodeling manifests itself in almost all cardiac 
diseases and was initially considered beneficial because 
it compensates for the increased hemodynamic overload 
and ventricular wall stress and optimizes both function and 
energy expenditure.1 In some circumstances, remodeling is 
also considered to be an adaptive phenomenon that increases 
heart performance during work overload. This phenomenon 
is a result of protein synthesis and either the incorporation 
of new units into contractile myocytes or the addition of 
new sarcomeres.3 Nevertheless, the benefits of this process 
are limited by the rate of maintenance, which promotes 
deleterious changes characterizing this feature as uniquely 
unfavorable.4724
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The mechanisms leading to myocardial injuries5-9 and 
hypertrophy10-12 during physiological or pathological states 
are different. For instance, the pathological hypertrophy 
results from the interaction of mechanical forces and 
neural and hormonal factors. Hemodynamic overload 
promotes myocyte stretch, the release of intracellular 
calcium, the activation of calcineurin and the induction 
of gene expression reprogramming.1 In athletes, left 
ventricular hypertrophy (LVH) is regarded as a physiological 
response that results from a hemodynamic overload; this 
physiological response does not result in the harmful effects 
of hypertension development or other heart diseases.10-12 
The literature explains physiological LVH as the result of 
a volume and pressure overload that results from intense 
physical training (the hemodynamic stimulus), which is not 
necessarily accompanied by neural and humoral changes.13
Despite  some  initial  benefits  of  physiological 
hypertrophy, it is difficult to determine the time at which 
physiological hypertrophy becomes pathological1 and 
represents a significant morbidity and mortality risk. In other 
words, it is difficult to pinpoint exactly when, during the 
natural development of hypertension, cardiac hypertrophy 
raises an individual’s risk of experiencing a cardiovascular 
event by a reported factor of six to eight times.3
There are well-known associations between LVH and 
several conditions, such as obesity, diabetes, myocardial 
infarction and even mild elevation in blood pressure,1 
as well as other cardiovascular risk factors that may 
be associated with increased cardiac mass regardless 
of ventricular pressure. Therefore, LVH is a powerful 
predictor of cardiovascular morbidity and mortality.3 
Clinical and experimental studies have reported that several 
pharmacological, hemodynamic and non-hemodynamic 
factors are able to induce, reverse and prevent LVH,14-16 
interstitial fibrosis17 and the progression of atherosclerotic 
effects on myocytes.18 Clinically, cardiac hypertrophy is 
associated with increased adverse events, including stroke, 
chronic renal failure, ventricular dysfunction, ventricular 
arrhythmias and sudden death.3 Cardiac hypertrophy is also 
associated with a higher prevalence of coronary disease 
and is related to endothelial dysfunction. This dysfunction 
may lead to myocardial ischemia, even in the absence of 
epicardial artery obstruction, by reducing coronary flow 
reserves due to various hemodynamic factors, such as a 
minimal reduction in coronary resistance, systolic coronary 
perivascular compression, collagen deposition, fibrosis and 
a lower production of local vasodilator substances, such as 
nitric oxide.19
After adjusting for other risk factors, Koren and 
coworkers20 reported a positive relationship between 
ventricular mass and geometry with the morbidity and 
mortality of patients who did not have complicated 
hypertension.20 The Framingham Heart Study, published 
by Levy et al21 included 3,220 healthy subjects aged 40 
years or older. This study demonstrated that estimating 
left ventricular mass by echocardiography can provide 
prognostic information about cardiovascular risk and can 
predict negative cardiovascular-related clinical events, 
including death.21 Moreover, LVH increased the risk of major 
cardiovascular events in 40% of the patients enrolled in the 
study.21
From these previous investigations, we infer that LVH 
constitutes an ominous risk factor for cardiovascular disease 
and that the magnitude of this risk is directly related to 
morbidity and mortality rates. Therefore, in this study, we 
endeavored to describe the effects of anti-hypertensive 
drugs on cardiac hypertrophy by a meta-analysis of previous 
studies. 
METHODS
The Medline (via PubMed), Lilacs and Scielo databases 
were searched using the following subject keywords: 
“cardiac hypertrophy,” “antihypertensive” and “mortality.” 
We also used the “related articles” function on PubMed, 
Lilacs and Scielo, which allowed us to search the references 
of the studies that were retrieved during our search. 
Publications were included in our review if either their 
titles or abstracts were available in English or Portuguese 
and suggested any effect (i.e., beneficial or malefic) or lack 
thereof from an anti-hypertensive treatment on cardiac 
hypertrophy. The review was completed in March, 2010. 
Publications were excluded if the treatment was limited to 
a particular technique or if the population received only one 
specific procedure (drug treatment) associated with a disease 
state or an age group. Other studies on anti-hypertensive 
treatment for hypertensive patients that offered additional 
relevant information found in the same database were also 
examined. Each publication was reviewed to identify the 
author(s), study period and data source, which influenced us 
to include the reference in the study.
RESULTS 
A total of 694 manuscripts met the inclusion criteria for 
our study. We excluded investigations in which treatment was 
limited to a particular method and those studies in which the 
study population was limited to patients who were undergoing 
a particular procedure or an associated disease state. 
In Table 1, we summarize studies that evaluated 
the relationship between anti-hypertensive drugs and 
cardiac hypertrophy. The investigations included in Table 725
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1 demonstrate the relevance of angiotensin-converting 
enzyme (ACE) inhibitors14,15,22-24 and angiotensin antagonist25 
treatment for cardiac hypertrophy regression.
DISCUSSION
Regression of left ventricular hypertrophy
The high prevalence of LVH and the high rate of 
complications of its condition necessitate a thorough 
understanding of the mechanisms involved in its etiology 
and development, as well as the importance of prevention 
and regression, to optimize and prevent the deleterious 
consequences. Thus, it is important to clarify the following 
issues, which are described below.
Relationship between LVH regression and cardiovascu-
lar morbidity and mortality
Several published reports have provided data indicating 
that anti-hypertensive drugs promote ventricular hypertrophy 
regression and myocardial repair. In particular, ACE 
inhibitors have shown promising cardio-protective effects 
in experimental models of hypertensive heart disease;22 
specifically, these inhibitors improve micro-vascular 
ischemia, ventricular function and arrhythmias.14-16, 23-29 We 
have previously reported that enalapril14 (ACE inhibitor) 
and verapamil23 (Ca++ channel blocker) provide the same 
cardio-protector response in an isoproterenol-induced LVH 
model in rats.28
To evaluate the effects of LVH and its regression, a 
previous study evaluated 151 patients with hypertension 
and LVH progression detected by echocardiography. The 
patients were followed for an average of 10 years+1.4 years, 
and the researchers noted a decrease in the non-fatal events 
rate following reduction of LVH, even after correcting for 
other risk factors. Conversely, the occurrence of these events 
increased when cardiac hypertrophy increased or remained 
stable.23
Another clinical investigation examined 430 patients 
with essential hypertension (also called primary or idiopathic 
hypertension) and related changes in the left ventricular mass 
with the occurrence of cardiovascular events. Treatments 
consisted of medication and lifestyle changes. At the 2 years 
and 9 months follow-up assessment, the prevalence of LVH 
by echocardiography was 26% per year, and the rate of 
cardiovascular events was 3.9% per year. For individuals who 
showed an improvement in LVH, the rate of cardiovascular 
events was 1.58 events per 100 patients per year. In the groups 
that experienced no change or a worsening in LVH, the rate 
of cardiovascular events was 6.27 events per 100 patients per 
year. These researchers also noted that this association did 
not depend on the initial ventricular mass, clinical parameters 
or monitored baseline blood pressure. Their final conclusion 
was that for primary hypertension, the decrease in ventricular 
mass during treatment is a favorable prognostic marker for 
subsequent morbid events.
Relationship between anti-hypertensive drugs and LVH 
regression 
With the exception of minoxidil and hydralazine, which 
are peripheral vasodilators, the other anti-hypertensive 
drugs provided full or partial LVH regression.28 Not all 
classification, prospective and randomized studies that have 
evaluated the effectiveness of various drugs with respect 
to left ventricular mass reduction have reported evidence 
of a difference between their effects on LVH regression.23 
Table 1 - A summary of the main clinical and experimental studies for anti-hypertensive drugs and left ventricular hyper-
trophy (LVH).
Author and year Main finding(s)
Costa et al., 199714 Enalaprilat inhibited isoproterenol-induced LVH action on cardiomyocytes, partially prevented the LVH and decreased 
the content of collagen fibers in rats.
Tan et al., 199222 Angiotensin-converting enzyme inhibition demonstrated promising myocardial remodeling effects in experimental 
models of hypertensive heart disease.
Bombig et al., 199623 Verapamil prevented the deleterious effects of isoproterenol in the myocardium of rats. This action was probably due to 
the prevention of myocardial hypertrophy and collagen tissue proliferation.
Sayegh F et al., 200524 Moexipril 15 mg once daily, administered for 24 weeks, resulted in a significant reversal of LVH in patients with es-
sential hypertension.
Dahlöf et al., 200225 Losartan prevented more cardiovascular morbidity and deaths than did atenolol while inducing a similar reduction in 
blood pressure and is better tolerated in humans. Losartan seemed to confer benefits beyond a reduction in blood pres-
sure.
Ferreira Filho et al., 200715 Enalaprilat increased the regression of hypertrophy in the left ventricle but not in the diaphragm or the gastrocnemius 
muscles.726
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However, in view of the different effects of the drugs, those 
drugs that depend on neural and humoral mechanisms, 
especially as reported in monotherapy studies, provide 
evidence that there may be several ways in which the drugs’ 
properties could reduce ventricular mass. In the literature, 
there are few monotherapy treatment meta-analyses. In 
addition, different groups report contradictory results.23 
Most studies have used anti-hypertensive drugs (i.e., beta-
blockers and diuretics) and reported 5-8% reductions of 
the left ventricular mass, while the use of ACE inhibitors 
and angiotensin AT1 blockers resulted in a 13% reduction. 
The difference between different anti-hypertensive drugs 
regarding their ability to reverse LVH may be determined by 
neural and humoral factors.30
Because LVH regression is an important intermediate 
objective of anti-hypertensive therapy, several trials and 
meta-analyses have compared the effects of these drugs on 
ventricular hypertrophy, but the usefulness of these studies 
is limited due to inadequate designs and methodological 
problems.32 The PRESERVE (Prospective Randomized 
Enalapril Study Evaluating Regression of Ventricular 
Enlargement),33 LIVE (Indapamide Sustained Release Versus 
Enalapril)34 and LIFE (Losartan Intervention for Endpoint 
in Hypertension)25 studies represent a new generation of 
well-planned trials comparing different anti-hypertensive 
drugs. These investigations revealed that during regression 
of LVH, the effects of nifedipine and enalaprilat are similar 
(PRESERVE); indapamine has a stronger effect than does 
enalapril (LIVE); and losartan treatment has a stronger effect 
than atenolol (LIFE).
The findings of these three studies conflict with the 
findings of some previous meta-analyses, and as such, 
these researchers have suggested that the effects of anti-
hypertensive drug must be evaluated individually on 
their important intermediate targets, such as LVH, with 
appropriate patient populations. The extrapolation of the 
LVH regression effects based on the anti-hypertensive drug 
classification may lead to clinical mistakes and needs to be 
carefully reconsidered.23
Mechanisms besides the decreased hemodynamic over-
load that may be responsible for LVH regression
A decrease in blood pressure may reduce a ventricular 
mass. In addition to clinical studies, experimental studies 
have demonstrated that LVH prevention and/or regression 
is independent of blood pressure. For instance, our group 
investigated isoproterenol-induced LVH in albino rats, 
which typically leads to hypertrophy without an increase 
in the after-load, and reported LVH regression by gavage 
administration of enalapril15, 16, 28, 31 and verapamil.23, 30
Moreover, studies in spontaneously hypertensive rats, a 
rat strain commonly used in our laboratory35-39, demonstrated 
that although various anti-hypertensive drugs may control 
systemic hypertension, LVH may be influenced by many, 
but not all, anti-hypertensive agents. Alpha-methyldopa, 
captopril, beta-blockers and calcium channel blockers 
promote the regression of hypertrophy, while other drugs, 
such as hydralazine and minoxidil, reduce blood pressure 
without influencing ventricular hypertrophy.23
However, the development of LVH in arterial hypertension 
may be explained primarily by an increased pressure overload 
and ventricular wall tension. The ratio of ventricular mass 
to pressure is often weak, even in relation to blood pressure 
monitored every 24 hours.3 Notably, LVH may occur 
independently from changes in arterial pressure and be present 
even when hypertension does not develop.1 We may include 
the presence of others factors involved in this condition, such 
as lifestyle, anthropometric and demographic characteristics, 
genetic influences and neural and humoral factors.24
Furthermore, in vivo, in vitro and genetic studies indicate 
that LVH development and its regression depends not only 
on the hemodynamic overload but also on other genetic, 
neural and humoral factors.9 Humoral agents that may affect 
mitogenesis and non-myocyte cardiomyocytes have been 
identified; these agents include the renin-angiotensin system, 
local norepinephrine, endothelin, transforming growth 
factor, insulin-like growth factor, bradykinin, prostaglandins 
and nitric oxide.23 The direct relationship between high 
blood pressure and LVH development has been questioned 
due to the fact that LVH development and its regression 
depends not only on the hemodynamic overload, forcing a 
review of the mechanisms involved in LVH development, 
such as the role of the sympathetic nervous system, the 
renin-angiotensin system, genetic factors, endothelin 
and endothelium.1 It is important to remember that the 
pathogenesis of LVH includes angiotensin II receptors and 
membrane-stretched cardiomyocytes.2
Several publications have reported that although anti-
hypertensive drugs show non-uniform effects on LVH, 
there are no concomitant proportional decreases in blood 
pressure.13, 20 Conversely, anti-hypertensive drugs have 
promoted different effects on LVH, despite inducing similar 
reductions in blood pressure.4 Those assumptions lead us to 
consider other mechanisms involved in LVH regression that 
are independent of blood pressure reduction.
Intrinsic properties of anti-hypertensives on LVH re-
gression: beyond blood pressure?
A decrease in cardiac mass may not depend only on 
daily arterial pressure measurement.23 Recently, Mayos 727
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et al.40 localized chromosome regions that harbor genetic 
variants that affect the diversity of electrocardiographic 
and echocardiographic LVH. They evaluated the genetic 
association of the Sokolow-Lyon voltage index and 
the Cornell product index, the septal thickness and the 
ventricular wall, ventricular dimensions and left ventricular 
mass in 868 members of 224 British households, all items 
were evaluated n pairs and together. Chromosomes 10, 
12 and 17 were the genetic loci involved and had the 
most important influence on LVH, as detected by the 
electrocardiogram.23
Genetic factors may explain a substantial portion of 
the quantitative variability in the electrocardiographic and 
echocardiographic examinations due to hemodynamic and/
or hormonal factors. However, the quantitative differences 
in LVH, known as phenotypes, may also be the result of 
individual differences besides those produced by the various 
anti-hypertensive drugs (i.e., beyond blood pressure).
CONCLUSION
LVH is an important marker of poor prognosis. Current 
medical literature shows the direct relationship between 
LVH and mortality, as well as the relationship between LVH 
regression and decreasing mortality. The literature also 
provides evidence for hypertrophic variations in response to 
the effect of different anti-hypertensive drugs and differences 
in the hemodynamic patterns.
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